Specify a stock or a cryptocurrency in the search bar to get a summary
Nutriband Inc
9WVNutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops AVERSA buprenorphine and AVERSA methylphenidate, and other transdermal pharmaceutical products. The company was incorporated in 2016 and is headquartered in Orlando, Florida. Address: 121 South Orange Avenue, Orlando, FL, United States, 32801
Analytics
WallStreet Target Price
18 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures 9WV
Dividend Analytics 9WV
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History 9WV
Stock Valuation 9WV
Financials 9WV
Results | 2019 | Dynamics |